Oral, Direct Factor Xa Inhibitor, BAY 59-7939, Given Once Daily in Patients Undergoing Total Hip Replacement - ODIXa-HIP


The goal of the trial was to evaluate treatment with rivaroxaban, an oral, direct Factor Xa inhibitor, compared with enoxaparin for prevention of thromboembolic disorders among patients undergoing elective total hip replacement.